Table 1 Baseline patient, disease and prior treatment characteristics
From: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Characteristics | N = 41 |
|---|---|
Median Age (Range) | 58 (33–82) |
Gender | Male: 29 (71%) |
Female: 12 (29%) | |
ECOG PS | 0: 15 (40%) |
1: 18 (47%) | |
2: 5 (13%) | |
Unknown: 3 | |
Race | Caucasian: 27 (68%) |
African American: 10 (25%) | |
Hispanic: 3 (7%) | |
Unknown: 1 | |
Histology | Papillary: 16 (39%) |
Unclassified: 14 (34%) | |
Chromophobe: 5 (12%) | |
Collecting Duct: 4 (10%) | |
Translocation: 1 (2%) | |
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC): 1 (2%) | |
Risk Group | MSKCC Criteria [15] |
Favorable: 8 (21%) | |
Intermediate: 25 (64%) | |
Poor: 6 (15%) | |
Unknown: 2 | |
IMDC Criteria [16] | |
Favorable: 10 (27%) | |
Intermediate: 23 (62%) | |
Poor: 4 (11%) | |
Unknown: 4 | |
Location of Metastases (more than 1 possible) | Retroperitoneal LNs: 26 (63%) |
Lung: 22 (54%) | |
Liver: 15 (37%) | |
Bone: 11 (27%) | |
Mediastinal LNs: 11 (27%) | |
Supraclavicular LNs: 7 (17%) | |
Mesenteric LNs: 5 (12%) | |
Pelvic Mass: 4 (10%) | |
Adrenal: 4 (10%) | |
Omentum: 3 (7%) | |
Pancreas, brain, contralateral kidney, soft tissue: 2 each (5%) | |
Spleen, diaphragm, gallbladder, iliac LNs: 1 each (2%) | |
Prior Nephrectomy | 29 (73%) |
Number of Prior Systemic Therapies | 0: 3 (8%) |
1: 25 (62%) | |
2: 8 (20%) | |
3 or more: 4 (10%) | |
Unknown: 1 | |
Prior Therapies (more than 1 possible) | Sunitinib: 26 (63%) |
Pazopanib: 11 (27%) | |
Axitinib: 4 (10%) | |
Everolimus: 4 (10%) | |
Cabozantinib: 3 (7%) | |
Gemcitabine/Cisplatin: 3 (7%) | |
Carboplatin/Taxol: 1 (2%) | |
Sorafenib: 1 (2%) | |
Bevacizumab/Everolimus: 1 (2%) | |
Prior Immunotherapy | Atezolizumab on trial: 1 (2%) Ipi/Nivo trial and J14186 HAR vaccine trial: 1 (2%) |